Spyre Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SYRE Nasdaq 2836 www.spyre.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spyre Therapeutics, Inc.

Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says - Oct 20th, 2026 10:48 am
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 - Oct 18th, 2026 7:30 am
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering - Oct 8th, 2026 11:15 am
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market - Oct 6th, 2026 11:40 am
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock - Oct 5th, 2026 6:13 pm
Spyre Therapeutics stock falls on public offering launch - Oct 5th, 2026 2:46 pm
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - Oct 5th, 2026 2:01 pm
Spyre Therapeutics Announces Grants of Inducement Awards - Oct 2nd, 2026 2:05 pm
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls - Oct 1st, 2026 7:38 am
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis? - Sep 22nd, 2026 10:16 am
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight - Sep 21st, 2026 11:00 am
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests - Sep 17th, 2026 1:04 am
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Sep 10th, 2026 5:59 pm
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - Sep 9th, 2026 7:56 am
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Sep 8th, 2026 6:00 am
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - Sep 3rd, 2026 2:05 pm
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Sep 3rd, 2026 9:30 am
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked - Aug 31st, 2026 8:59 pm
Spyre Therapeutics Plunges; Why Analysts Aren't Sweating - Aug 26th, 2026 2:04 pm